Authors
Latest:
Ready, Set, Cabenuva: Implementing Cabotegravir/RilpivirineThis novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.
Latest:
When Climate Change Gets Personal: The Expanding Threat of Mosquito HabitatsAs someone who lives with the long-term effects of chikungunya, Camillo Mora PhD, sees the expanding habitat of mosquitos and is concerned more people will be exposed to vector-borne illnesses and deal with not only the acute phases of these viruses but also the possibility of long-term health effects they can present.
Latest:
Unmasking the Infodemic: The Impact of COVID-19 Misinformation on Public HealthSocial media platforms, public health agencies, and communities must join forces to stop the rapid spread of false information.
Latest:
Climate Change Effects on Vector-Borne Disease: The Case of LymeWith evolving weather patterns, the natural habitat of ticks is expanding, and more people are becoming susceptible to them.
Latest:
Emerging Infectious Diseases During COVID-19In this era of increasingly mobile and connected populations, it is possible for an infection to spread around the world in 24 to 48 hours.
Latest:
Identifying Invasive Pneumococci in Pediatric Infections Utilizing Whole Genome SequencingThis method represents a significant advancement in case management for this population. In our latest From Pathogen to Infectious Disease Diagnosis Podcast, Jose Alexander, MD, ABMM, ABAIM, FCCM, CIC, ASCP, BCMAS, provides insights on its capabilities and how it can potentially aid clinicians in reducing antimicrobial resistance.
Latest:
Doravirine and Islatravir Combination Shown to be Noninferior to Once-Daily ARTIn a blinded phase 3 study, doravirine and islatravir was compared to antiretroviral therapy, BIC/FTC/TAF (Biktarvy), and it was shown that there was no between-group differences in mean change in CD4 T-cell or total lymphocyte count at week 48.
Latest:
Bictegravir vs Darunavir in Advanced HIV: Results from the LAPTOP TrialGeorg Behrens, MD, PhD, highlights superior virological suppression and immune recovery with bictegravir-based therapy in therapy-naïve individuals with advanced HIV disease.
Latest:
Are We at a Breaking Point for Adoption of Updated Susceptibility Interpretive Criteria?The implementation of new College of American Pathologists rules presents an opportunity for collaboration between clinical microbiology laboratories and infectious disease pharmacists and physicians.
Latest:
The Future and Resources in HCV CareExpert hepatologists discuss future developments in HCV that they are excited about and provide resources for new providers to get started on delivering HCV care.
Latest:
The Overlooked Tropical Diseases You May Not Know AboutOver 1 billion people are estimated to be affected by 20 conditions of neglected tropical diseases (NTDs), though they are often unheard of by many. Heather Saunders, MPH, RN, CIC, delves into 5 of these diseases and discusses efforts to stop their spread.
Latest:
HIV: Treating Patients with Viral MutationsSorana Segal-Maurer, MD, offers clinical insights on treating patients with HIV who have viral mutations, including M184V, highlighting guideline recommendations.
